In BRAF/MEK inhibition-resistant cancer cells carrying BRAFV600E mutation, the dual MAPK inhibition drives the overexpression of FGF1 followed by the FGFR activation and the reactivation of ERK [62]. Here, MAP2K7 is linked to cancer.